Boosting lubricin to protect knees after ACL and other knee injuries
Official title: Small molecule stimulation of lubricin for treatment of post-traumatic osteoarthritis
Funded at University of Central Florida · NIH-11170609 · Data updated 2026-11-12
Researchers are trying to find FDA-approved drugs that raise lubricin, a natural joint lubricant, to help people with knee injuries like ACL tears avoid post-traumatic osteoarthritis.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project start | August 15, 2024 |
| Project end | August 14, 2026 |
| Funding year | 2025 |
| Award (this year) | $151,615 |
| NIH project number | 5R21AR082984-02 |
| Project ID | NIH-11170609 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who have had a recent ACL tear or other significant knee injury and are at risk for developing post‑traumatic osteoarthritis would be the likely future candidates.
✕Less likely to help
Patients with long-standing, severe osteoarthritis or joint damage unrelated to injury are unlikely to benefit from these early-stage approaches.
What this research studies
This project uses human cartilage cells that were engineered to signal when they produce lubricin, and researchers will screen approved drugs in a 3D cartilage model that mimics injured joints. Compounds that increase lubricin in the lab model will be studied further in cell tests and then in mice given a non‑invasive ACL tear to see if joint damage is reduced. The work is primarily laboratory and animal research now, intended to identify drug candidates that could later move toward human testing.
Why it matters
Potential benefit: If successful, this could lead to medicines that boost joint lubrication and slow or prevent arthritis after knee injuries.
How similar studies have gone: Delivering lubricin by gene therapy prevented osteoarthritis in mice, but pharmacologically stimulating lubricin with approved drugs in people is a newer and largely untested strategy.
Where this research is happening
-
University of Central Florida
Orlando, United States Active
Researchers
- Principal investigator: Kean, Thomas J. — University of Central Florida
- Study coordinator: Kean, Thomas J.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.